Incretin-based Therapy in Early Diagnosed Type 1 Diabetes

NCT02908087 · Completed

Last updated 2026-05-28

This clinical trial is testing whether incretin-based therapy can help preserve insulin production in people who have recently been diagnosed with type 1 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 13 people

Who can join Ages 10–30 · all sexes

Timeline Started 2016-03 · est. completion 2021-05

Where 4 sites · Finland, Sweden

What this study is testing ClinicalTrials.gov NCT02908087 ↗

Description as written by the study sponsor.

The main objective of the trial is to study whether daily treatment with liraglutide improves insulin secretion and reduces the requirement of exogenous insulin, and whether liraglutide treatment is tolerable and safe in subjects aged 10-30 years, having an early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT), and treated with insulin.

Treatments tested

Victoza® (liraglutide) Drug

Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
Placebo Drug

Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.

Main thing measured	Serum C-peptide AUC
Sponsor	University of Oulu
Conditions studied	Type 1 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02908087 ↗